Drug Eluting Balloons Catheters Market Outlook 2026–2030 Exploring New Business Opportunities

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Drug Eluting Balloons Catheters Market During 2026–2030?

The drug eluting balloons catheters market size has demonstrated rapid expansion in recent years. Its valuation is anticipated to increase from $1.65 billion in 2025 to $1.86 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.5%. The expansion observed historically can be linked to the rising prevalence of coronary artery disease, the increasing acceptance of percutaneous coronary interventions, enhancements in balloon catheter materials, the clinical endorsement of paclitaxel-coated devices, and the wider establishment of interventional cardiology centers.

The drug eluting balloons catheters market is anticipated to experience substantial growth over the coming years. This market is projected to reach a valuation of $2.92 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 11.9%. The expansion throughout the forecast period is propelled by factors such as the increasing demand for minimally invasive vascular therapies, the rising adoption of sirolimus-based balloons, the broadening of peripheral vascular disease treatments, growing investments in next-generation catheter technologies, and a heightened focus on long-term patient outcomes. Significant trends expected during this period involve the increasing embrace of drug-coated balloon technologies, their growing utilization in coronary and peripheral interventions, a developing preference for stent-free treatment options, the advancement of sophisticated drug coating techniques, and an intensified focus on preventing restenosis.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13429&type=smp

Which Major Factors Are Driving The Expansion Of The Drug Eluting Balloons Catheters Market?

The expansion of the drug-eluting balloon catheter market is anticipated due to the increasing incidence of peripheral and cardiovascular diseases. Cardiovascular diseases (CVDs) encompass conditions affecting the heart and circulatory system, while peripheral artery disease (PAD) involves constricted arteries leading to diminished blood flow, mainly in the limbs. Drug-eluting balloon catheters serve as a treatment for coronary artery disease (CAD), utilizing a semi-compliant angioplasty balloon covered with an anti-proliferative agent that delivers an anti-restenotic impact upon entering a blood vessel. As an illustration, data from January 2024, provided by the American Heart Association, a US-based non-profit organization, indicated that the age-adjusted mortality rate for cardiovascular disease climbed to 233.3 deaths per 100,000 in 2024, marking a 4.0% year-on-year increase from 224.4 deaths per 100,000 in 2023. Consequently, the increasing occurrence of both peripheral and cardiovascular diseases is a key driver for the drug-eluting balloon catheter market.

How Are The Various Segments Of The Drug Eluting Balloons Catheters Market Categorized?

The drug eluting balloons catheters market covered in this report is segmented –

1) By Product: Coronary Artery Disease, Peripheral Vascular Disease, Drug-Eluting Balloon Catheters

2) By Drug: Paclitaxel, Sirolimus, Other Drugs

3) By Raw Material: Nylon, Polyurethane, Other Raw Materials

4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories

Subsegments:

1) By Coronary Artery Disease: Coronary Drug-Eluting Balloon Catheters, Coronary In-Stent Restenosis Drug-Eluting Balloon Catheters, Coronary Small-Vessel Drug-Eluting Balloon Catheters

2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters, Femoro-Popliteal Drug-Eluting Balloon Catheters, Below-the-Knee (BTK) Drug-Eluting Balloon Catheters

3) By Drug-Eluting Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters

What Trends Are Affecting The Expansion Of The Drug Eluting Balloons Catheters Market?

Leading companies operating within the drug-eluting balloon catheter market are intensifying their focus on creating next-generation products equipped with advanced technologies to gain a competitive edge. For instance, in March 2024, Boston Scientific Corporation, a US-based biomedical/biotechnology engineering firm and multinational manufacturer of medical devices, announced it had secured U.S. Food and Drug Administration (FDA) approval for the AGENT Drug-Coated Balloon (DCB). AGENT DCB is the inaugural drug-coated coronary balloon available in the U.S. for treating in-stent restenosis (ISR), a condition where plaque or scar tissue blocks a stented vessel. It incorporates a paclitaxel coating that delivers a therapeutic dose to the vessel wall, thereby reducing ISR recurrence without needing additional stents or radiation. Clinical trials demonstrated a 49% reduction in heart attack risk at the target site and reported low rates of adverse events.

Which Major Firms Influence Developments In The Drug Eluting Balloons Catheters Market?

Major companies operating in the drug eluting balloons catheters market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB

Read the full drug eluting balloons catheters market report here:

https://www.thebusinessresearchcompany.com/report/drug-eluting-balloons-catheters-global-market-report

Which Region Currently Holds The Largest Share Of The Drug Eluting Balloons Catheters Market?

North America was the largest region in the drug eluting balloons catheters market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Drug Eluting Balloons Catheters Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13429&type=smp

Browse Through More Reports Similar to the Global Drug Eluting Balloons Catheters Market 2026, By The Business Research Company

Drug Coated Balloons Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-coated-balloons-global-market-report

Pta Balloon Catheter Market Report 2026

https://www.thebusinessresearchcompany.com/report/pta-balloon-catheter-global-market-report

Deflectable Catheters Market Report 2026

https://www.thebusinessresearchcompany.com/report/deflectable-catheters-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795